Viewbix Announces Quantum X Labs' Provisional Patent Filing On 'Generating Quantum Markov Chain Monte Carlo Sampling Points For Continuous Distribution Functions'

This advancement has the potential to transform conventional "flat" clinical trial data into detailed quantum-resolved biological maps

Tel Aviv, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Viewbix Inc. (NASDAQ:VBIX) ("Viewbix" or the "Company"), an advanced technologies company, announced today a significant intellectual property milestone achieved by Quantum X Labs.

Quantum X Labs has filed a provisional patent application titled "Generating Quantum Markov Chain Monte Carlo Sampling Points for Continuous Distribution Functions".

This innovative technology leverages quantum computing to enhance Markov Chain Monte Carlo (MCMC) methods, enabling more efficient sampling from complex continuous probability distributions.

In collaboration with its portfolio company Cliniquantum, Quantum X Labs is pioneering the application of this quantum-enhanced approach to potentially revolutionize clinical trials. The methodology aims to uncover hidden biological structures and non-linear dependencies across molecular and patient data layers, allowing for the identification of latent patient clusters, precise molecular response signatures, and probabilistic treatment-response modelling- with higher resolution and potentially requiring fewer samples than traditional classical methods.

This advancement has the potential to transform conventional "flat" clinical trial data into detailed quantum-resolved biological maps, converting historically underpowered datasets into robust mechanistic evidence. As quantum computers mature and process vast configurations in parallel, this technology positions Viewbix, through its proposed acquisition of Quantum X Labs, to capture significant value in the pharmaceutical and drug discovery markets by accelerating personalized medicine, reducing trial costs and timelines, and improving success rates.

Viewbix recently signed a definitive agreement to acquire up to 100% (and not less than 85%) of Quantum X Labs, encompassing its expanding patent portfolio, including prior IP in quantum error correction. The acquisition is expected to close within 90 days of the date of execution of the definitive agreement, which was December 15, 2025, subject to final due diligence, regulatory approvals, the approval of the Company's stockholders in accordance with applicable rules or regulations of the Nasdaq Stock Market LLC and customary closing conditions.